Publication in Nature Communications highlights the preclinical development of SYNB1891

(MacDougall Biomedical Communications, Inc.) Synlogic today announced the publication in Nature Communications of preclinical data supporting its first clinical immuno-oncology program, SYNB1891, which is being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphoma.